Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer



Status:Completed
Conditions:Cancer, Cancer, Gastrointestinal, Gastrointestinal, Pancreatic Cancer
Therapuetic Areas:Gastroenterology, Oncology
Healthy:No
Age Range:18 - 90
Updated:4/21/2016
Start Date:May 2007
End Date:November 2011

Use our guide to learn which trials are right for you!

The investigators hypothesize that the CXCR2 ligands/CXCR2 biological axis plays an
important role in promoting angiogenesis in PC; and that the genetic changes and the
microenvironment of the tumor regulate the expression of CXCR2 ligands/CXCR2 in PC in order
to potentiate their angiogenic phenotype. A corollary of this hypothesis is that the cell
surface receptors (CXCR2) and the intracellular signaling pathways that mediate the
angiogenic responses induced by ELR+ CXC-chemokines are potential targets for novel
therapeutic interventions in PC.


Inclusion Criteria:

- Normal subjects - No documented clinical history of pancreatic diseases supported by
at least 1 negative imaging test. (EUS, Ct scan or MRI)

- Chronic pancreatitis - Documented diagnosis of moderate to advanced chronic supported
bpancreatitisy at least 1 positive imaging test. (EUS, Ct scan or MRI)

- Pancreatic Cancer - Documented tissue diagnosis (or clinical suspicion) of Pancreatic
Cancer.

Exclusion Criteria:

- Exclusion criteria will include age younger than 18 yrs, pregnancy, previous
pancreatic or gastric resection, and inability to tolerate routine endoscopy with
conscious sedation
We found this trial at
1
site
4201 Belfort Road
Jacksonville, Florida 32216
(408) 293-2336
Mayo Clinic Mayo Clinic's campus in Arizona provides medical care for thousands of people from...
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials